The Possible Associaton Between Cerebral Venous Thrombosis and COVID-19 Infecton in a Patent WithSickle Cell Disease: A Case Report

Athena Sharifi Razavi; Narges Karimi

doi:10.18502/crcp.v5iS1.6239

Athena Sharifi Razavi Clinical Research Development Unit of Bou-Ali Sina Hospital, Mazandaran University of Medical Science, Sari, Iran.
Narges Karimi Immunogenetics Research Center, Toxoplasmosis Research Center, Clinical Research Development Unit of Bou-Ali Sina Hospital, Mazandaran University of Medical Science, Sari, Iran.

DOI: https://doi.org/10.18502/crcp.v5iS1.6239

Keywords: COVID-19; Coronavirus; Cerebral venous thrombosis; Sickle cell disease

Abstract

Background: The most common symptom of the novel Coronavirus Disease 2019 (COVID-19) infection is fever and dyspnea that leads to hypoxia in severe cases. Some COVID-19 patients experience neurological symptoms, including ischemic stroke and intracerebral hemorrhage. Sickle Cell Disease (SCD) is a hypercoagulable state, however, it has not been approved as a significant cause of Cerebral Venous Thrombosis (CVT).

Case presentation: In this case report, we described CVT in an SCD patient who had COVID-19, as well. We reported a 32-year-old man with a history of sickle cell anemia presented with left hemiparesis, headache, and seizure. After evaluation of the patient, CVT accompanied by COVID-19 infection was diagnosed. He was treated with intravenous unsaturated heparin, antiepileptic drugs, and antiviral agents with a favorable outcome. Based on our knowledge, this is the first case study to describe an association between CVT and COVID-19 infection in a patient with SCD.

Conclusion: During the recent pandemic, vaso-occlusive attacks in SCD patients can be evaluated for COVID-19 as an etiological factor.